Compare QLYS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QLYS | PTCT |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 2012 | 2006 |
| Metric | QLYS | PTCT |
|---|---|---|
| Price | $176.06 | $72.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 17 |
| Target Price | ★ $133.08 | $80.65 |
| AVG Volume (30 Days) | 732.2K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.99 | ★ 264.48 |
| EPS | ★ 2.91 | 0.90 |
| Revenue | ★ $321,607,000.00 | $264,734,000.00 |
| Revenue This Year | $9.97 | N/A |
| Revenue Next Year | $7.15 | $17.70 |
| P/E Ratio | ★ $61.33 | $78.96 |
| Revenue Growth | 15.32 | ★ 36.19 |
| 52 Week Low | $74.51 | $48.86 |
| 52 Week High | $201.54 | $90.87 |
| Indicator | QLYS | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 47.26 |
| Support Level | $130.78 | $63.29 |
| Resistance Level | $199.13 | $73.86 |
| Average True Range (ATR) | 7.52 | 2.03 |
| MACD | -1.97 | 0.19 |
| Stochastic Oscillator | 8.02 | 64.68 |
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.